Clinical Trials Browser

Phase 1/2 × INDUSTRY × Maximum Tolerated Dose × Clear all

NCT03838367 2025-09-09

Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

Phase 1/2 Terminated

10 enrolled 15 charts

Triple Negative Breast Neoplasms